Rebif (Interferon beta-1a)

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsing Multiple Sclerosis (RMS)

Conditions

Relapsing Multiple Sclerosis (RMS)

Trial Timeline

Jun 30, 2016 → Jul 27, 2020

NCT ID

NCT02921035

About Rebif (Interferon beta-1a)

Rebif (Interferon beta-1a) is a pre-clinical stage product being developed by Merck for Relapsing Multiple Sclerosis (RMS). The current trial status is completed. This product is registered under clinical trial identifier NCT02921035. Target conditions include Relapsing Multiple Sclerosis (RMS).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02921035	Pre-clinical	Completed	Jun 30, 2016	Jul 27, 2020	Relapsing Multiple Sclerosis (RMS)
NCT01075880	Pre-clinical	Completed	May 1, 2009	Jun 1, 2013	Multiple Sclerosis, Relapsing-Remitting

Competing Products

20 competing products in Relapsing Multiple Sclerosis (RMS)

See all competitors

Product	Company	Stage	Hype Score
Placebo + Pirtobrutinib	Eli Lilly	Phase 2	52
CT-P53 + US-Ocrevus + EU-Ocrevus	Celltrion	Phase 3	77
LY2127399 + Placebo	Eli Lilly	Phase 2	52
dirucotide + placebo	Eli Lilly	Phase 2/3	65
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	52
Daclizumab	AbbVie	Phase 3	77
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	52
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccine	AbbVie	Phase 2	52
BIIB019 (Daclizumab)	AbbVie	Phase 3	77
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process Placebo	AbbVie	Phase 3	77
Rebif (Interferon beta-1a)	Merck	Pre-clinical	23
Interferon beta-1a	Merck	Pre-clinical	23
Rebif New Formulation + prophylactic Ibuprofen + Rebif New Formulation + ibuprofen PRN	Merck	Phase 3	77
Rebif® + Avonex®	Merck	Phase 3	77
Rebif® + Rebif®	Merck	Approved	85
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) alone	Merck	Phase 2	52
Placebo + IFN beta-1a + Methylprednisolone	Merck	Phase 2	52
Interferon beta-1a (Rebif)	Merck	Approved	85
Teriflunomide + Evobrutinib	Merck	Phase 3	77
Cladribine + Placebo + Microgynon®	Merck	Phase 1	33

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved